Systemic sclerosis patients with interstitial lung disease (SSc-ILD) have a great deal of symptoms and comorbidities (other diseases), with a high impact on their overall biological and physical stability, or frailty. The study, “Severity and features of frailty in systemic sclerosis-associated interstitial lung disease,” was published in the journal Respiratory…
News
Preclinical Study Shows IVA337’s Potential in Treating SSc Skin and Cardiovascular Complications
Inventiva’s lead therapy candidate IVA337 for the treatment of systemic sclerosis (SSc) was shown to prevent the progression of lung fibrosis and the remodeling of blood vessels in preclinical animal models of lung fibrosis and systemic sclerosis. These findings will be the…
Patients with scleroderma may develop calcinosis, a condition marked by abnormal deposits of calcium salts in the body’s soft tissues, a new study says. The study, “Are there risk factors for scleroderma-related calcinosis?,” was published in the journal Modern Rheumatology. “Calcinosis is commonly found in pressure areas such…
Cytori’s Habeo Cell Therapy Appears to Benefit Scleroderma Patients with Diffuse Form of the Disease
Cytori Therapeutics’ Habeo Cell Therapy may be effective only in scleroderma patients who have the more severe diffuse version of the disease, a Phase 3 clinical trial indicates. The trial failed to meet its main goal of improving all scleroderma patients’ hand function. Subgroup analyses indicated that those with…
The 19th Annual Scleroderma Foundation National Patient Education Conference is expected to bring together over 600 scleroderma patients, their families, friends, caretakers, and some of the world’s leading healthcare professionals and researchers. As previously announced, the conference will take place this week, July 21–23, in Chandler, Arizona. The venue…
Scleroderma patients without pulmonary arterial hypertension (PAH) were found to develop a mild but significant decline in the ability to exercise and in pulmonary vascular function during exercise, according to a four-year prospective study published in the European Respiratory Journal. Previous large-scale studies have demonstrated that PAH is a real and severe complication…
Certain immune cells contribute to the development of fibrosis, researchers at Chicago’s Northwestern Medicine discovered in a study that might overturn the view of lung fibrosis as a disease unaffected by immune processes. The report titled, “Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life…
The American Medical Association is adding descriptions of Cytori Therapeutics’ cell-based therapy for scleroderma of the hands to its authoritative database of medical procedures, services and technology. Because so many players in the American healthcare system use the database as a reference, the addition of the descriptions will help Cytori spread the word…
Systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH) show high serum levels of adipsin, a peptide secreted from adipose tissue. Researchers believe adipsin could be used as a potential biomarker for SSc-PAH in these people. The finding was reported in the study, “Elevated Adipsin Levels are…
Today is the World Scleroderma Day, and to mark the occasion the Scleroderma Foundation is hosting a virtual “stepping out to cure scleroderma” walk-a-thon. The online initiative is an opportunity to connect with friends, family and supporters, and take part in an event to honor — or in memory of…
Recent Posts
- No key immune complications reported with experimental cell therapy
- Cell therapy linked to skin improvements in scleroderma trial
- Scleroderma patients open to aesthetic treatments, survey finds
- New anti-scarring pill shows encouraging safety in early trial
- No-touch light test may help in monitoring scleroderma skin changes
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds